

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ACN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adem Karafili
Date of last notice	4 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ankara Holdings Pty Ltd <The Ankara Family Trust>* (Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
Date of change	31 December 2025
No. of securities held prior to change Ankara Holdings Pty Ltd <The Ankara Family Trust>*	2,562,389 fully paid ordinary shares 74,739 unlisted options with an exercise price of \$0.4482 expiring on 13 January 2029 500,000 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025. 1,000,000 unlisted options with an exercise price of \$0.2882 expiring on 1 December 2026.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

<p>Ankara Holdings Pty Ltd ATF A&N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>53,571 unlisted options issued under the EIP exercisable at \$0.4742 per option and expiring on 22 July 2027</p>
Class	Unlisted Options
Number acquired	Nil
Number disposed	500,000 unlisted options
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and estimated valuation</p>	N/A
<p>No. of securities held after change</p> <p>Ankara Holdings Pty Ltd <The Ankara Family Trust>*</p> <p>Ankara Holdings Pty Ltd ATF A&N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>2,562,389 fully paid ordinary shares</p> <p>74,739 unlisted options with an exercise price of \$0.4482 expiring on 13 January 2029</p> <p>1,000,000 unlisted options with an exercise price of \$0.2882 expiring on 1 December 2026.</p> <p>53,571 unlisted options issued under the EIP exercisable at \$0.4742 per option and expiring on 22 July 2027</p>
<p>Nature of change</p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Cancellation of unlisted options due to expiry.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	

+ See chapter 19 for defined terms.

Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ACN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Margaret Hardin
Date of last notice	4 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust (Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
Date of change	31 December 2025
No. of securities held prior to change Margaret L Hardin Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust* *(Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)	53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027 372,463 Fully Paid Ordinary Shares 166,667 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025.
Class	Unlisted Options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	Nil
Number disposed	166,667 Unlisted Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change Margaret L Hardin Margaret L Hardin as trustee for Margaret L Hardin Revocable 2013 Trust* *(Margaret Hardin has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)	53,571 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027 372,463 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of unlisted options due to expiry.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	

+ See chapter 19 for defined terms.

Interest after change	
-----------------------	--

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ACN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nicholas Berry
Date of last notice	13 May 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Pure Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund (Mr Berry is deemed to have the same relevant interests in securities that Pure Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act)
Date of change	31 December 2025
No. of securities held prior to change Pure Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund* *Mr Berry is deemed to have the same relevant interests in securities that Pure Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act.	73,142,547 fully paid ordinary shares 52,442,532 unlisted warrants 6,686,844 unlisted options @ \$0.07 EXP 31/12/25
Class	Unlisted Options
Number acquired	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	6,686,844 unlisted options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change Pure Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund* *Mr Berry is deemed to have the same relevant interests in securities that Pure Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act.	73,142,547 fully paid ordinary shares 52,442,532 unlisted warrants
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of unlisted options due to expiry.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	<p>The Company has entered into the following agreements with Pure Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund (Pure):</p> <ul style="list-style-type: none"> • A\$12m two-tranche secured loan facility dated 17 October 2022 (Original Facility) and Warrant Deed; and • a variation to the Original Facility pursuant to which Pure may extend three additional tranches of funding to the Company dated 27 March 2024 (Amended Facility) and Second Warrant Deed. <p>Under the Original Facility and Warrant Deed, Pure is entitled to be issued a number of Tranche B Warrants on draw down of the Second Loan. Please refer to ASX announcement dated 17 October 2022 for further details.</p> <p>Under the Amended Facility and Second Warrant Deed, Pure is entitled to be issued a number of Tranche D and Tranche E warrants to be calculated at the time the Fourth and Fifth Loans are respectively drawn down. Please refer to ASX announcement dated 27 March 2024 for further details.</p>
Nature of interest	Mr Berry is deemed to have the same relevant interests in securities that Pure Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act.
Name of registered holder (if issued securities)	J P Morgan Nominees Pty Ltd
Date of change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	<p>The number of Tranche B warrants to be issued will be calculated by dividing the Second Loan Amount by an amount equal to the Tranche B Exercise Price, which is calculated at the time of utilisation of the Second Loan.</p> <p>The number of Tranche D warrants to be issued will be calculated by dividing the Fourth Loan Amount by an amount equal to the Tranche D Exercise Price, which is calculated at the time of utilisation of the Fourth Loan.</p> <p>The number of Tranche E warrants to be issued will be calculated by dividing the Fifth Loan Amount by an amount equal to the Tranche E Exercise Price, which is calculated at the time of utilisation of the Fifth Loan.</p>
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.